Differential Thrombogenesis by EPA and DHA Mediated by HDL

NCT06494488 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Lipid Metabolism Disorders
Hypertriglyceridemia

Interventions

DRUG: EPA
DRUG: DHA

Sponsor

The Miriam Hospital

Collaborators

[object Object]
[object Object]